Stay updated on Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page.

Latest updates to the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page
- Check4 days agoChange DetectedThe core trial purpose wording was clarified to compare relatlimab+nivolumab with nivolumab monotherapy; an EU CT Number was added and the old EudraCT Number replaced, along with a new MedlinePlus link and updated revision/date stamps.SummaryDifference1%
- Check11 days agoChange DetectedThe page has been updated to version 3.0.1, and the section on Melanoma related topics from MedlinePlus Genetics has been removed.SummaryDifference0.3%
- Check18 days agoChange DetectedThe webpage has undergone significant updates, including the addition of numerous facility names and locations across various countries, as well as new MedlinePlus related topics on melanoma and cancer immunotherapy. Additionally, several references to studies and articles related to advanced melanoma treatments have been included.SummaryDifference17%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.8%
Stay in the know with updates to Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Relatlimab Combo VS Nivolumab Alone in Melanoma Clinical Trial page.